The aim of the study is to assess the efficacy and safety of intra - detrusor injections of Dysport versus placebo in subjects suffering from neurogenic detrusor overactivity following spinal cord injury or multiple sclerosis.
- Registry ID
- EUCTR2010-023210-31
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Ipsen Innovation
- Start date
- 2012-09-06
- Completion date
- 2013-03-21
- Last update
- 2026-08-16
Conditions
- NEUROGENIC DETRUSOR OVERACTIVITY
Summary
The primary study objective is to assess the efficacy of a single dose of Dysport (750 U) compared to placebo for the improvement in the daily incontinence episode frequency (IEF) for each administration mode (15 or 30 injection sites).
Locations
- , , Austria
- , , Lithuania
- , , Italy
- , , Germany
- , , Czechia
Related clinical trials
- A PHASE 2/3, OPEN-LABEL, BASELINE-CONTROLLED, MULTICENTER, LONG-TERM STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF VIBEGRON IN PEDIATRIC SUBJECTS 2 YEARS TO < 18 YEARS OF AGE WITH NEUROGENIC DETRUSOR OVERACTIVITY (NDO) ON CLEAN INTERMITTENT CATHETERIZATION (CIC)
- A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT FOR THE TREATMENT OF URINARY INCONTINENCE IN SUBJECTS WITH NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY OR MULTIPLE SCLEROSIS
View on source registry